Treats chronic idiopathic constipation (CIC). ANDA 219220, held by Ajanta Pharma Ltd. Prucalopride Succinate.
As of Nov 16, 2026, ANDA 219220 (Prucalopride Succinate), held by Ajanta Pharma Ltd, was first approved by FDA on Jan 16, 2026, with 0 approved supplements and 0 published complete response letters.
Prucalopride tablets are indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 16, 2026 | Original application | Approved | None posted |
| Prucalopride SuccinateEQ 1MG BASE · tablet;oral | Prucalopride Succinate | Rx |
| Prucalopride SuccinateEQ 2MG BASE · tablet;oral | Prucalopride Succinate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters